Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Infinity Pharmaceuticals Inc (NASDAQ: INFI) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Infinity Pharmaceuticals Inc (NASDAQ: INFI) concerning whether a series of statements by Infinity Pharmaceuticals Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On June 14, 2016, Infinity Pharmaceuticals revealed that the Company will be reducing its workforce by 21% following unsatisfactory drug-study results. A Phase 2 study of its treatment for non-Hodgkin lymphoma met its primary endpoint of overall response rate; Infinity Pharmaceuticals said it hoped it would provide a larger clinical benefit.

Following this news, NASDAQ: INFI stock fell as much 69% during intraday trading on June 14, 2016.

Based in Cambridge, Massachusetts, Infinity Pharmaceuticals Inc develops and delivers medicines to patients with difficult to treat diseases.

If you purchased shares of Infinity Pharmaceuticals Inc (NASDAQ: INFI) on or before June 14, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185